CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		98 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
OPERATING EXPENSES
General and administrative	$ 480	$ 391	$ 1,297	$ 2,354	$ 31,019
Research and development	667	1,226	1,626	4,684	101,675
Purchased in-process research and development	0	0	0	0	34,311
Other	0	0	0	0	(375)
Total operating expenses	1,147	1,617	2,923	7,038	166,630
Interest and other income, net	(5)	(2)	(93)	(16)	(13,851)
Loss from continuing operations before taxes	1,142	1,615	2,830	7,022	152,779
Income tax benefit		0	0	0	(1,355)
Loss from continuing operations	1,142	1,615	2,830	7,022	151,424
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	0	0	(2,202)
Net Loss	1,142	1,615	(2,830)	(7,022)	(149,222)
Less: Net Loss attributable to the noncontrolling interest	(191)	0	(191)	0	(191)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 951	$ 1,615	$ 2,639	$ 7,022	$ 149,031
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.02	$ 0.04	$ 0.06	$ 0.17
Basic and diluted shares outstanding (in shares)	40,885	40,775	40,879	40,775